



Figure 1




= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP
 FOR EXAMPLE:
 DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)
 (2) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
 LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3






Figure 4



POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT
L = GLYCERYL or B THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE that is optionally absent

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY


iB = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY or iB OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR

PHOSPHORODITHIOATE OPTIONALLY PRESENT

Figure 6



A

5'-[R1]-NNNNNNNNNNNNNNNNNNNN X X
← NNN X X
3'-EXTENSION

B

5'-[R1]-NNNNNNNNNNNNNNNNNNNN X X
3'-[R2]-NNNNNNNNNNNNNNNNNNNN X X

MELT AND CLONE

C

5'-[R1]-NNNNNNNNNNNNNNNNNNNN XXXXXXXXXXXXXXXX NNNNNNNNNNNNNNNNNNNNN-3'
3'-[PRIMER]-5'

U6 snRNA PROMOTER TERMINATION REGION

R1 = RESTRICTION SITE #1
R2 = RESTRICTION SITE #2
N = A, G, C, or T
X = A, G, C, or T LOOP SEQUENCE

A

```

    5'-[R1] NNNNNNNNNNNNNNNNNNNNNN [R2] X X
           |                             |   |
           +----->                   X X X
                                     R2
          3'-EXTENSION
          
```


B

```

    5'-[R1] NNNNNNNNNNNNNNNNNNNNNN [R2] X X
    3'-[R1] NNNNNNNNNNNNNNNNNNNNNN [R2] X X
          
```

CLEAVAGE WITH RESTRICTION ENZYMES 1 AND 2

C


```

    5'-[ ] NNNNNNNNNNNNNNNNNNNNNN [ ]
    3'-[ ] NNNNNNNNNNNNNNNNNNNNNN [ ]
          
```

CLONE

U6 snRNA PROMOTER U6 snRNA PROMOTER

R1 = RESTRICTION SITE #1
R2 = RESTRICTION SITE #2
N = A, G, C, or T
X = A, G, C, or T




Chemical structures 1-10 showing various bisecting triantennary N-glycan structures. Each structure consists of a core fucose (B) and a terminal galactose (G) linked via a bisecting triantennary N-glycan. The structures are numbered 1 through 10, corresponding to the labels in the original image.

R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl

B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy



**Figure 12: Inhibition of VEGF-Induced Angiogenesis
 by siRNAs**




Figure 13: A375 24h 36B4 VEGFR1 mRNA Expression







Figure 14: Phosphorylated siNA constructs



Phosphates can be modified
as described herein



Asymmetric duplex
siNA



(n) = number of base
pairs (e.g. 3-18 bp)

[illegible]

Figure 16: siNA Targeting VEGFR-1 Inhibits VEGF-Induced Rat Corneal Angiogenesis




Figure 17: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (intraocular administration)




Figure 18: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (periocular administration)




Figure 19: Inhibition of Mouse CNV with anti-VEGFR-1 siNA (periocular administration)





Figure 20: Inhibition of Mouse 4T1 Mammary Tumors with siNA targeting VEGFR1 site 349



**Figure 21: Inhibition of Mouse 4T1 Mammary Tumors with siNA targeting VEGFR1 site 349
Decreased level of Soluble VEGFR1**




Figure 22A: Inhibition of VEGFR1 RNA expression with siNAs targeting VEGFR1 and VEGFR2 homologous sequences




Figure 22B: Inhibition of VEGFR1 RNA expression with siNAs targeting VEGFR1 and VEGFR2 homologous sequences




Figure 23A: Inhibition of VEGFR2 RNA expression with siNAs targeting VEGFR1 and VEGFR2 homologous sequences




Figure 23B: Inhibition of VEGFR2 RNA expression with siNAs targeting VEGFR1 and VEGFR2 homologous sequences




Figure 24: Inhibition of VEGF Induced Ocular Angiogenesis with siNAs targeting VEGFR1 and VEGFR2 homologous sequences

